Investigations of survivin: the past, present and future

Front Biosci (Landmark Ed). 2011 Jan 1;16:952-61. doi: 10.2741/3728.

Abstract

Survivin is a member of the inhibitors-of-apoptosis protein (IAPs) family. It promotes cell survival through interference with multiple cell cycle-related proteins such as INCENP and Aurora B kinase. Survivin also inhibits cell death through interference with both caspase-dependent and -independent cell apoptosis. Interestingly, recent evidence suggests that survivin may also play a role in the regulation of cancer cell autophagy. At the clinical level, studies on clinical specimens have shown that survivin expression is up-regulated in various human cancers and its up-regulation is associated with tumour resistance to both chemotherapy and radiation therapy. On the basis of these findings, survivin has been proposed as an attractive target for new anti-cancer interventions. However, despite the role that survivin plays in cancer cell survival and anti-drug response, the development of survivin inhibitors is relatively slow as compared to other therapeutic inhibitors for cancer treatment. In this review, the relationships between survivin expression and the causation of drug resistance in cancers are re-addressed. This review also summarizes the recent development of survivin inhibitors for clinical usage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm
  • Humans
  • Imidazoles / therapeutic use
  • Inhibitor of Apoptosis Proteins / genetics
  • Inhibitor of Apoptosis Proteins / metabolism
  • Microtubule-Associated Proteins* / biosynthesis
  • Microtubule-Associated Proteins* / genetics
  • Naphthoquinones / therapeutic use
  • Neoplasms / genetics
  • RNA, Small Interfering / therapeutic use
  • Survivin

Substances

  • BIRC5 protein, human
  • Imidazoles
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Naphthoquinones
  • RNA, Small Interfering
  • Survivin
  • YM 155